Oral Estradiol: Compounded vs. Branded, A Complete Clinical Comparison

What is actually different between compounded and FDA-approved oral estradiol?

Estradiol is an FDA-approved prescription estrogen sold as generic oral tablets, and also as transdermal patches, gels, creams and vaginal products, which are separate products [2][3]. The approved tablet label covers moderate to severe vasomotor symptoms of menopause, moderate to severe vulvar and vaginal atrophy, hypoestrogenism from hypogonadism, castration or primary ovarian failure, palliation in selected breast and prostate cancer, and prevention of postmenopausal osteoporosis [2].

The difference that matters here is review. FDA states that compounded drugs are not FDA-approved, that it does not verify their safety, effectiveness or quality before they are marketed, and that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug [1]. It also draws a line between generic and compounded: a generic drug is approved by FDA and must establish therapeutic equivalence to the brand-name drug, while a compounded drug is not approved [1].

FDA names the quality failures it is concerned about: poor compounding practices can produce contamination, or a drug that contains too much or too little active ingredient [1].

Who regulates a compounding pharmacy?

Oversight depends on the type of compounder. State boards of pharmacy have primary responsibility for day-to-day oversight of state-licensed pharmacies that are not registered with FDA as outsourcing facilities, though FDA still conducts surveillance and for-cause inspections of those pharmacies [1]. Outsourcing facilities register with FDA, are subject to current good manufacturing practice requirements, are inspected by FDA on a risk-based schedule, and must report adverse events and give FDA information about the products they compound [4].

Congress passed the Drug Quality and Security Act, enacted in November 2013, in response to the 2012 fungal meningitis outbreak and other serious adverse events linked to poor-quality compounded drugs. In that outbreak, contaminated drugs compounded by a Massachusetts pharmacy led to more than 750 cases of infection and more than 60 deaths in 20 states [4].

Why someone might be prescribed a compounded estradiol tablet

FDA's own examples of appropriate compounding are a patient with an allergy to a certain dye who needs the drug made without it, or an older patient or a child who cannot swallow a tablet and needs a liquid [1]. The estradiol tablet label notes that the 2 mg tablet contains FD&C Yellow No. 5 (tartrazine), which may cause allergic-type reactions, including bronchial asthma, in susceptible people [2].

What the FDA-approved oral estradiol label says

This section draws on the oral estradiol tablet label (Teva, DailyMed version 16) [2]. Its usual initial dose for menopausal symptoms is 1 to 2 mg of estradiol daily, adjusted to control symptoms, with cyclic administration (for example 3 weeks on and 1 week off) [2]. The label says to use the lowest effective dose and the shortest duration consistent with treatment goals, to reassess at 3- to 6-month intervals, and to attempt to taper or stop at 3- to 6-month intervals [2].

The tablet label still carries the older two-part boxed warning: 'ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER' and 'CARDIOVASCULAR AND OTHER RISKS' [2]. It cites the Women's Health Initiative results for oral conjugated estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg in women 50 to 79, including more myocardial infarction, stroke, invasive breast cancer, pulmonary embolism and deep vein thrombosis, and the WHIMS finding of more probable dementia in women 65 and older [2]. The label also says that other doses of oral conjugated estrogens with medroxyprogesterone, and other combinations and dosage forms, were not studied in WHI and that, absent comparable data, those risks should be assumed to be similar [2].

That wording is being replaced product by product. On 2025-11-10 FDA asked makers of menopausal hormone therapy to remove boxed-warning language on cardiovascular disease, breast cancer and probable dementia (while keeping the endometrial cancer boxed warning on systemic estrogen-alone products), to remove the recommendation to use the lowest effective dose for the shortest time, and to add consideration of starting therapy for moderate to severe vasomotor symptoms in women under 60 or within 10 years of menopause [5]. FDA approved the first six revised labels on 2026-02-12 (Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva) and said 29 companies had submitted proposed changes [6][7]. FDA's list of updated products does not include oral estradiol tablets or estradiol patches, and as of 2026-10-29 the oral estradiol tablet label still carries the older wording [6][7][2].

The label also lists drug interactions: CYP3A4 inducers such as St. John's wort, phenobarbital, carbamazepine and rifampin may lower estrogen concentrations and reduce effect or change the bleeding pattern, while inhibitors such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may raise them and cause side effects [2].

Do the large safety trials apply to compounded estradiol?

The trial that shaped estrogen warnings did not test estradiol at all. WHI's estrogen-plus-progestin arm randomized 16,608 women aged 50 to 79 with a uterus to conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg daily or placebo and was stopped after a mean of 5.2 years; hazard ratios were 1.29 for coronary heart disease, 1.26 for invasive breast cancer, 1.41 for stroke and 2.13 for pulmonary embolism [8]. The estrogen-alone arm randomized 10,739 women with prior hysterectomy to conjugated equine estrogen 0.625 mg daily or placebo over an average of 6.8 years [9]. The Climara patch label notes that only daily oral conjugated estrogens 0.625 mg were studied in the estrogen-alone substudy and that the relevance of the findings to lower doses, other routes of administration or other estrogen-alone products is not known [3].

So the largest body of safety evidence describes a different estrogen product from either the branded or the compounded estradiol tablet.

Route versus brand: where the clot signal actually sits

The observational data compare the oral route with the transdermal route, not one manufacturer or one tablet with another. In the French ESTHER case-control study, 271 women with a first idiopathic venous thromboembolism were compared with 610 matched controls; the adjusted odds ratio for venous thromboembolism in current users was 4.2 (95% CI 1.5 to 11.6) for oral estrogen and 0.9 (95% CI 0.4 to 2.1) for transdermal estrogen [10]. In a meta-analysis of eight observational studies and nine randomized trials, the pooled observational results gave odds ratios for a first venous thromboembolism of 2.5 (95% CI 1.9 to 3.4) with oral estrogen and 1.2 (95% CI 0.9 to 1.7) with transdermal estrogen; oral risk was highest in the first year of use (4.0, 95% CI 2.9 to 5.7), and the authors wrote that transdermal estrogen 'may be safer' [11].

The route-specific estimates are observational, and the transdermal labels still carry clot warnings and contraindications [3]. The Climara label does state one pharmacokinetic difference between the routes: systemic availability of estradiol after transdermal use is about 20 times higher than after oral use because there is no first-pass metabolism [3].

Progestin and the uterus

The oral estradiol label says that when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be initiated to reduce the risk of endometrial cancer, and that a woman without a uterus does not need progestin [2]. The label reports that the endometrial cancer risk among unopposed estrogen users is about 2- to 12-fold greater than in non-users, with the greatest risk after prolonged use (15- to 24-fold for 5 to 10 years or more), and that adding a progestin reduces the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer [2]. The label also calls for adequate diagnostic measures, including endometrial sampling when indicated, in cases of undiagnosed persistent or recurring abnormal vaginal bleeding [2].

What to watch for on the approved tablets

The oral label lists reactions reported with estrogen therapy without giving frequencies: breast tenderness, enlargement and pain; nausea, vomiting, abdominal cramps and bloating; headache, migraine and dizziness; changes in vaginal bleeding; edema; weight change; mood changes; gallbladder disease; chloasma; and increased blood pressure [2]. Its contraindications include undiagnosed abnormal genital bleeding, known or suspected or prior breast cancer (except selected patients treated for metastatic disease), known or suspected estrogen-dependent neoplasia, active or prior deep vein thrombosis or pulmonary embolism, active or recent arterial thromboembolic disease, liver dysfunction or disease, known hypersensitivity to the ingredients, and known or suspected pregnancy [2].